Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Biol Cell
2004 Mar 01;153:963-72. doi: 10.1091/mbc.e03-07-0478.
Show Gene links
Show Anatomy links
Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski.
Takeda M
,
Mizuide M
,
Oka M
,
Watabe T
,
Inoue H
,
Suzuki H
,
Fujita T
,
Imamura T
,
Miyazono K
,
Miyazawa K
.
???displayArticle.abstract???
c-Ski is a transcriptional corepressor that interacts strongly with Smad2, Smad3, and Smad4 but only weakly with Smad1 and Smad5. Through binding to Smad proteins, c-Ski suppresses signaling of transforming growth factor-beta (TGF-beta) as well as bone morphogenetic proteins (BMPs). In the present study, we found that a mutant of c-Ski, termed c-Ski (ARPG) inhibited TGF-beta/activin signaling but not BMP signaling. Selectivity was confirmed in luciferase reporter assays and by determination of cellular responses in mammalian cells (BMP-induced osteoblastic differentiation of C2C12 cells and TGF-beta-induced epithelial-to-mesenchymal transdifferentiation of NMuMG cells) and Xenopus embryos. The ARPG mutant recruited histone deacetylases 1 (HDAC1) to the Smad3-Smad4 complex but not to the Smad1/5-Smad4 complex. c-Ski (ARPG) was unable to interact with Smad4, and the selective loss of suppression of BMP signaling by c-Ski (ARPG) was attributed to the lack of Smad4 binding. We also found that c-Ski interacted with Smad3 or Smad4 without disrupting Smad3-Smad4 heteromer formation. c-Ski (ARPG) would be useful for selectively suppressing TGF-beta/activin signaling.
Figure 1. c-Ski (ARPG) selectively suppressed TGF-β signaling. Luciferase reporter assay was conducted using (CAGA)9-MLP-Luc (A, top) and 3GC2-Lux (B, bottom). Cells were stimulated with TGF-β (2.5 ng/ml) (A) or BMP-7 (500 ng/ml) (B). □, unstimulated samples; ▪, ligand-stimulated samples. Expression of recombinant proteins was determined by immunoblotting analysis of the cell lysates using anti-Flag M2 antibody (bottom).
Figure 2. c-Ski (ARPG) failed to inhibit BMP-induced osteoblastic differentiation of C2C12 cells. C2C12 cells were infected with adenoviruses carrying various cDNAs, followed by BMP-6 treatment (200 ng/ml) for 96 h. Osteoblastic differentiation was monitored by induction of alkaline phosphatase activity (top). □, unstimulated samples; ▪, BMP-6–stimulated samples. Expression of recombinant proteins was determined by immunoblotting analysis of the cell lysates using anti-Flag M2 antibody (bottom).
Figure 3. Inhibition of TGF-β–induced EMT in NMuMG cells by c-Ski and c-Ski (ARPG). NMuMG cells were infected with adenoviruses carrying various cDNAs, followed by TGF-β treatment (5 ng/ml). Twenty-four hours after ligand stimulation, cell morphology was observed under microscopy. Control cells (left panels) and TGF-β–treated cells (right panels) are shown for noninfected cells (A) and cells infected with adenoviruses carrying LacZ (B), Smad7 (C), c-Ski (D), and c-Ski (ARPG) (E).
Figure 4. Effects of c-Ski (ARPG) on signaling of TGF-β superfamily in Xenopus embryos. (A) Effect on endogenous BMP signaling using whole embryos. Equivalent amounts (500 pg) of RNAs encoding c-Ski, c-Ski (ARPG), or β-globin were injected near the ventral midline of four-cell Xenopus embryos. Resultant phenotypes in a representative experiment are shown (left, c-Ski; middle, c-Ski (ARPG); and right, β-globin). (B) Effect on endogenous BMP signaling in animal caps. RNA encoding c-Ski or c-Ski (ARPG) was injected into the animal pole of four-cell embryos. Animal caps were excised at brastulla stage 8 and cultured until stage 23. RNAs were then extracted from the animal caps and expression of marker genes (muscle actin and NCAM) was analyzed by RT-PCR. Histone H4 was used as a loading control. (C) Effect on activin signaling in animal caps. RNA encoding c-Ski or c-Ski (ARPG) was injected together with RNA encoding activin into the animal pole of four-cell embryos, and expression of marker genes was analyzed as described above.
Figure 5. Interaction of c-Ski (ARPG) with Smad proteins. (A) Recruitment of HDAC1 to activated Smad complexes by c-Ski and c-Ski (ARPG) and (B) binding of c-Ski and c-Ski (ARPG) to each of the Smad proteins. COS-7 cells were transfected with indicated plasmids. Smad proteins (A) or c-Ski (B) was immunoprecipitated from cell lysates and coprecipitated proteins were visualized by immunoblotting. ALK-5TD and ALK-6QD are constitutively active forms of ALK-5 and ALK-6, respectively. (C) c-Ski (ARPG) suppression of TGF-β signaling was dependent on R-Smad binding. c-Ski (Δ40) lacks the N-terminal 40 amino acid residues and therefore cannot bind Smad2/3. c-Ski (ARPGΔ40) is a double mutant of (ARPG) and (Δ40). Luciferase reporter assay was conducted in HepG2 cells stimulated with TGF-β (2.5 ng/ml) using (CAGA)9-MLP-Luc. □, unstimulated samples; ▪, TGF-β–stimulated samples.
Figure 6. Selective loss of suppression of BMP signaling by c-Ski W274E mutant. (A) Luciferase reporter assay in HepG2 cells stimulated with TGF-β or BMP-7 using (CAGA)9-MLP-Luc (left) and 3GC2-Lux (right), respectively. □, unstimulated samples; ▪, ligand-stimulated samples. (B) Recruitment of HDAC1 to activated Smad complexes. COS-7 cells were transfected with indicated plasmids. Smad proteins were immunoprecipitated from cell lysates and coprecipitated proteins (c-Ski and HDAC1) were visualized by immunoblotting. ALK-5TD and ALK-6QD are constitutively active forms of ALK-5 and ALK-6, respectively.
Figure 7. Effects of c-Ski proteins on complex formation of Smad proteins. COS-7 cells were transfected with various combination of cDNAs (Smad3, Smad4, c-Ski, and ALK-5TD). c-Ski (wild-type or mutant) or Smad4 was immunoprecipitated and coprecipitated proteins were visualized by immunoblotting. Effect of c-Ski W274E on complex formation was examined by immunoprecipitating c-Ski W274E (A) or Smad4 (B). Effect of c-Ski (ARPG) (C), c-Ski ΔS2/3 (D), or wild-type c-Ski (E) was examined by immunoprecipitating c-Ski proteins. Effects of increasing amounts of c-Ski proteins on heteromer formation were also examined by immunoprecipitating Smad4 (F).
Figure 8. Schematic model of inhibition of Smad signaling by c-Ski (A), c-Ski (ARPG) (B), v-Ski (C), and v-Ski (ARPG) (D). c-Ski possesses a Smad2/3 binding region as well as Smad4 binding region, whereas c-Ski (ARPG) lacks a Smad4 binding region, causing failure of c-Ski (ARPG) to inhibit BMP signaling. v-Ski, which has truncated structure in the N- and C- termini of c-Ski, lacks a Smad2/3 binding region and one of the mSin3A binding regions. v-Ski inhibits TGF-β/activin signaling as well as BMP signaling through interaction with Smad4. v-Ski (ARPG) does not inhibit Smad signaling because it no longer interacts with Smad proteins.
Akhurst,
TGF-beta antagonists: why suppress a tumor suppressor?
2002, Pubmed
Akhurst,
TGF-beta antagonists: why suppress a tumor suppressor?
2002,
Pubmed
Akiyoshi,
c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads.
1999,
Pubmed
Amaravadi,
Autonomous neural axis formation by ectopic expression of the protooncogene c-ski.
1997,
Pubmed
,
Xenbase
Asahina,
Human osteogenic protein-1 induces both chondroblastic and osteoblastic differentiation of osteoprogenitor cells derived from newborn rat calvaria.
1993,
Pubmed
Attisano,
Smads as transcriptional co-modulators.
2000,
Pubmed
Bakin,
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.
2000,
Pubmed
Bhowmick,
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.
2001,
Pubmed
Cho,
Molecular nature of Spemann's organizer: the role of the Xenopus homeobox gene goosecoid.
1991,
Pubmed
,
Xenbase
Colmenares,
The ski oncogene induces muscle differentiation in quail embryo cells.
1989,
Pubmed
Colmenares,
Transformation-defective v-ski induces MyoD and myogenin expression but not myotube formation.
1991,
Pubmed
Correia,
Sedimentation studies reveal a direct role of phosphorylation in Smad3:Smad4 homo- and hetero-trimerization.
2001,
Pubmed
Dennler,
Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.
1998,
Pubmed
Derynck,
Smads: transcriptional activators of TGF-beta responses.
1998,
Pubmed
Fujii,
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation.
1999,
Pubmed
Fumagalli,
Expression of the c-ski proto-oncogene in human melanoma cell lines.
1993,
Pubmed
Goldman,
Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression.
1996,
Pubmed
He,
The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins.
2003,
Pubmed
Inman,
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
2002,
Pubmed
Ishida,
Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter.
2000,
Pubmed
Katagiri,
Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage.
1994,
Pubmed
Kawabata,
Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.
1998,
Pubmed
Li,
Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene.
1986,
Pubmed
Liu,
Ski/Sno and TGF-beta signaling.
2001,
Pubmed
Luo,
The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling.
1999,
Pubmed
Massagué,
Controlling TGF-beta signaling.
2000,
Pubmed
Miettinen,
TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors.
1994,
Pubmed
Miyazawa,
Two major Smad pathways in TGF-beta superfamily signalling.
2002,
Pubmed
Miyazono,
Divergence and convergence of TGF-beta/BMP signaling.
2001,
Pubmed
Mizuide,
Two short segments of Smad3 are important for specific interaction of Smad3 with c-Ski and SnoN.
2003,
Pubmed
Muraoka,
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
2002,
Pubmed
Nakao,
Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.
1999,
Pubmed
Nakayama,
Xenopus Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning.
1998,
Pubmed
,
Xenbase
Nomura,
Isolation of human cDNA clones of ski and the ski-related gene, sno.
1989,
Pubmed
Nomura,
Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor.
1999,
Pubmed
Oft,
Metastasis is driven by sequential elevation of H-ras and Smad2 levels.
2002,
Pubmed
Ota,
Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
2002,
Pubmed
Piek,
TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells.
1999,
Pubmed
Piek,
Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis.
2001,
Pubmed
Prunier,
The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation.
2003,
Pubmed
Qin,
Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control.
2002,
Pubmed
Reed,
Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling.
2001,
Pubmed
Shi,
Mechanisms of TGF-beta signaling from cell membrane to the nucleus.
2003,
Pubmed
Stavnezer,
The v-ski oncogene encodes a truncated set of c-ski coding exons with limited sequence and structural relatedness to v-myc.
1989,
Pubmed
Sun,
Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling.
1999,
Pubmed
Wang,
Ski represses bone morphogenic protein signaling in Xenopus and mammalian cells.
2000,
Pubmed
,
Xenbase
Wu,
Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling.
2002,
Pubmed
Xu,
Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor.
2000,
Pubmed
Yang,
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
2002,
Pubmed
